Dapsone 6.5% | Niacinamide 3%
Dapsone 6.5% | Niacinamide 3% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This compounded topical preparation combines dapsone 6.5% and niacinamide 3% for the prescriber-directed management of inflammatory acne vulgaris. Dapsone inhibits neutrophil-mediated inflammatory damage in the pilosebaceous unit; niacinamide provides complementary anti-inflammatory activity via NF-κB inhibition, supports skin barrier function by stimulating ceramide synthesis, and reduces post-inflammatory hyperpigmentation. This two-agent formulation provides dual-axis anti-inflammatory coverage with favorable tolerability. Genesis Compounding prepares this as a prescription-only 503A compounded preparation for patient-specific use.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Dapsone 6.5% | Sulfone anti-inflammatory and antimicrobial agent that inhibits neutrophil myeloperoxidase-driven cytotoxicity and LTB4-mediated chemotaxis in acne lesions, reducing neutrophilic tissue destruction at inflamed follicles. |
| Niacinamide 3% | Topical vitamin B3 derivative that suppresses NF-κB-mediated inflammatory cytokine production in keratinocytes, stimulates stratum corneum barrier lipid synthesis, reduces sebum production, and inhibits melanosome transfer—complementing dapsone's anti-inflammatory activity and reducing post-acne hyperpigmentation. |
Route: Topical application to acne-affected skin areas as directed.
- Apply a thin layer to affected facial and/or body areas once or twice daily per prescriber direction.
- Rub in gently until absorbed.
- Avoid eyes, lips, and mucous membranes.
- For topical use only.
Prescriber-determined; general guidance:
- Apply once daily (preferred evening) to affected areas.
- Formal acne response assessment at 8–12 weeks of consistent use.
- Duration and frequency are individualized; prescriber will adjust based on clinical response and tolerance.
- Dapsone (6.5%): Mechanism in topical acne is not fully characterized. Anti-inflammatory effects dominate: inhibits myeloperoxidase-peroxide-halide cytotoxic system in neutrophils; suppresses LTB4 chemotaxis; reduces neutrophil adhesion to IgA. Bacteriostatic effects on C. acnes may also contribute via PABA-competitive inhibition of dihydropteroate synthase in the bacterial folic acid pathway.
- Niacinamide: Inhibits PARP-1 and NF-κB transcription factor activation in keratinocytes, reducing expression of IL-1α, IL-6, TNF-α, and CXCL8; upregulates ceramide synthase expression, increasing ceramide, cholesterol, and sphingolipid content of the stratum corneum; suppresses sebocyte lipid production; reduces melanosome transfer from melanocytes to keratinocytes, mitigating post-inflammatory hyperpigmentation.
This formulation is suitable for mild to moderate inflammatory acne vulgaris, particularly in patients who experience tolerance issues with retinoids or benzoyl peroxide, or for whom a non-retinoid anti-inflammatory approach is preferred. The niacinamide component provides barrier support to mitigate the drying effects of dapsone and addresses post-acne hyperpigmentation.
Prescriber monitoring:
- Screen for G6PD deficiency in at-risk populations.
- Avoid concurrent oral dapsone, antimalarials, or TMP-SMX (systemic dapsone levels and hemolytic risk).
- Reassess response at 8–12 weeks; consider adding a retinoid or benzoyl peroxide if inadequate response.
Contraindications:
- G6PD deficiency or methemoglobinemia
- Hypersensitivity to dapsone or sulfonamides
- Concurrent oral dapsone or antimalarial use
Warnings & Precautions:
- Methemoglobinemia with concurrent oxidizing agents (TMP-SMX, nitrates, benzocaine).
- Yellow/orange skin discoloration with same-time application of benzoyl peroxide; apply at different times of day.
- Pregnancy: Category C for oral dapsone; discuss risk-benefit for topical use with prescriber.
Drug Interactions:
- TMP-SMX: increases systemic dapsone and metabolite levels; avoid.
- Benzoyl peroxide: temporary skin discoloration; stagger application times.
- Antimalarials: increased hemolytic risk; avoid combination.
Common Side Effects: Application site dryness, erythema, and peeling (dapsone vehicle); niacinamide is very well-tolerated; rare methemoglobinemia.
Store at controlled room temperature (20–25°C / 68–77°F). Protect from heat and light. Do not freeze. Keep tightly sealed. Use before the beyond-use date assigned by Genesis Compounding. Keep out of reach of children.
How does this two-ingredient formula work for acne?
Dapsone targets the neutrophil-driven inflammatory destruction that turns clogged follicles into red, swollen papules and pustules—its anti-inflammatory action reduces inflammatory acne lesion count. Niacinamide works through a different pathway (NF-κB inhibition) to reduce inflammatory cytokine production in skin cells, while also improving skin barrier function and reducing post-acne dark spots. Together they attack acne inflammation from two different molecular angles.
Is dapsone at 6.5% different from the FDA-approved 7.5%?
The compounded 6.5% concentration is between the commercially available 5% and 7.5% dapsone gels. Your prescriber has customized this dose for your specific clinical needs and tolerance profile. The mechanism and safety considerations are the same as for the FDA-approved preparations.
Will this help with dark spots left from previous acne?
Yes—niacinamide has evidence for reducing post-inflammatory hyperpigmentation by inhibiting the transfer of melanosomes (pigment granules) from melanocytes to skin cells. This effect is gradual and typically requires several weeks to months of consistent use.
Is this product FDA-approved?
No. This is a 503A compounded topical preparation from Genesis Compounding for a specific patient. Dapsone at 5% and 7.5% is FDA-approved for acne vulgaris; this combination with niacinamide at these concentrations is a compounded preparation not independently FDA-approved.
Can I use this if I am taking trimethoprim-sulfamethoxazole (Bactrim) for another condition?
No—TMP-SMX increases systemic dapsone and its metabolite levels even when dapsone is applied topically, increasing the risk of methemoglobinemia. Inform your prescriber of all current medications before starting dapsone topically.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.